Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study

作     者：Yao Xie, Dao-Zhen Xu, Zhi-Meng Lu, Kang-Xian Luo, Ji-Dong Jia, Yu-Ming Wang,Gui-Zhen Zhao, Shu-Lin Zhang and Da-Zhi Zhang Department of Infeetious Diseases , Beijing Ditan Hos-pital, Beijing 100011 , China Department of Infec-tious Diseases, Ruijin Hospital, Shanghai 200025, China De-partment of Infectious Diseases, Naifang Hospital, First Military Medical U-niversity, Guangzhou 510515, China (Luo KX) Center of Liver Disease,Beijing Friendship Hospital, Beijing 100050, China (Jia J D ) Institute ofInfectious Disease, Southwest Hospital, Third Military Medical University,Chongqing 410032, China Department of Infectious Disea-ses, Second Hospital, China Medical University, Shenyang 110004, China Department of Infectious Diseases, First Hospital, Xi’ an Jiao-tong University, Xi’ an 710061 , China ) Liver Disease Centerof Chongqing, Second Hospital, Chongqing Medical University,Chongqing 410010, China 

作者机构：Department of Infectious Diseases Beijing Ditan Hospital Beijing 100011 China. xieyao@*** 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2004年第3卷第3期

页      面：369-374页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：hepatitis C virus genotype chronic hepatitis C interferon PEG-IFN 

摘      要：BACKGROUND: Some factors have been reported to besassociated with a greater likelihood of sustained viral re-sponse ( SVR) in the interferon (IFN) treatment of chronichepatitis C. The factors include HCV genotype, HCVRNA level in serum, state of liver disease, baseline bodyweight, age, sex, and race. The aim of this trial was to in-vestigate the influence of HCV genotype on the IFN treat-ment of patients with chronic hepatitis ***: The genotypes of HCV virus were determinedin the patients with chronic hepatitis C from several hospi-tals of China enrolled into the randomized, opened andcontrolled trial of Peg-IFN alpha-2a (pegasys) treatment,controlled with IFN-α-2a (roferon-A). The serum ALTlevels and HCV RNA concentrations of the patients weredetected before and at the end of treatment and during thefollow-up. The influence of HCV genotype on the IFNtreatment of patients with chronic hepatitis C was analyzedin intention-to-treat (ITT) ***: The HCV genotypes of 202 patients were deter-mined. Of these patients, 158(78.22%) were infected withgenotype 1 HCV and 44(21.78%) with genotype *** viral response at the end of treatment (ETVR) andsustained viral response (SVR) rates were 53.80% and25.32% respectively in patients with genotype 1 HCV, butthey were 61.36% and 43.18% in patients with genotypenon-1. The difference of SVR between patients with geno-type 1 HCV and those with genotype non-1 was significant(P =0.021). After being grouped by the used drugs, theETVR rates of patients infected with genotype 1 and non-1HCV were 76.83% and 80.95% in the patients treated withpegasys (P =0.686); but their SVR rates were 35.37% and66.67% (P =0. 01). The viral relapse rate of genotype 1HCV (55.56%) was significantly higher than that of geno-type non-1 HCV (23.53%) (P=0.02). In roferon-A group,the ETVR and SVR rates of patients with genotype 1 HCVwere 28.95% and 14.47% respectively, which were lowerbut not more significant than those of patients with ge